Elanco Announces the Approval of Increxxa™

Increxxa™ (tulathromycin injection) Approved by FDA for  U.S. Veterinarians and Swine Producers.

Elanco Animal Health Incorporated (NYSE: ELAN) has announced the U.S. FDA approval of Increxxa™ (tulathromycin injection) for the treatment of swine respiratory disease (SRD).

A new tulathromycin choice for effective SRD control and treatment, Increxxa’s addition to the Elanco SRD portfolio means Elanco now has one of the broadest SRD control and treatment portfolios in the industry.

“We recognize what a challenge respiratory disease can be for the livestock industry and are excited to offer Increxxa to veterinarians and producers, giving them yet another solution to help combat this problematic disease in swine,” said Jose Simas, executive vice president, U.S. farm animal business at Elanco. “Like all Elanco products, veterinarians and producers can be confident that Increxxa is held to the company’s uncompromising standard of potency, uniformity and quality. Elanco is committed to offering a broad portfolio of products to keep livestock healthy,” Simas noted. “With the availability of Increxxa, producers now have another strong option to support the responsible use of antibiotics in their herds.”

For swine, Increxxa becomes another product within Elanco’s SRD portfolio, allowing producers the opportunity to find the proper solution needed for their respiratory disease. Balancing whole herd health with individual pig solutions, Increxxa is a single-dose application licensed for the treatment and control of SRD in swine. Producers have long understood that SRD leads to negative impacts on performance as well as increased mortality, causing substantial production and economic losses.1 By quickly targeting and rapidly circulating at the site of infection, with its long half-life Increxxa controls SRD early while providing pigs more time to mount an effective SRD defense.2,3* A balance of speed and persistence*, Increxxa is supported by Elanco’s industry-leading technical team and unwavering quality assurance – finding individual solutions for each challenge, like SRD.

“The addition of Increxxa to Elanco’s portfolio continues to strengthen the tool chest against swine diseases in our modern production systems. Our product portfolio offers multiple active ingredients, multiple routes of administration and multiple label indications, leading to more innovative veterinarian-derived treatment and control options,” said Dr. Eric Christianson, Elanco consulting veterinarian.

Increxxa Injectable Solution is indicated for the treatment of SRD, associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.

Learn more about Increxxa at www.increxxaswine.com.